Prognostic Impact of Mediastinal Lymph Nodes in Interstitial Lung Diseases: Is Environmental Exposure the Offender?
To the Editor:
We read with great interest the work of Adegunsoye and colleagues showing a significant association between enlarged mediastinal lymph nodes (MLNs) on chest computed tomography and survival in patients with interstitial lung diseases (ILDs) (1) . They report a 66% prevalence of enlarged MLNs according the type of ILD, with various potential causes of development as previously pointed out. The authors raise the hypothesis that enlarged MLNs may be reflective of underlying immunologic phenomena in lung tissue, which in turn contribute to the pathophysiology of disease progression in pulmonary fibrosis. However, we suggest that the potential involvement of environmental exposures in ILDs, particularly anthracosis, should be discussed. Anthracosis caused by coal dust and other environmental factors such as air pollution, biomass fuels used extensively for cooking ("hut lung"), and cigarette smoking is also known to be a source of damage in MLNs (2) .
A broad array of inhaled exposures are risk factors for developing an ILD, particularly idiopathic pulmonary fibrosis (IPF) in genetically susceptible patients (3) . Inhaled agents are known to induce a series of lesions in alveolar epithelial cells, causing a biochemical oxidant injury and thereafter an immunological response when healing mechanisms (e.g., inflammation, coagulation, and epithelial repair) are put in place, resulting in pulmonary fibrosis. It is very likely that MLNs are involved in this process. Indeed, autopsy studies have revealed higher levels of inorganic particles, such as silicon and aluminum, in the MLNs of patients with IPF compared with controls (3).
Interestingly, inhalation of occupational dusts may be an aggravating factor associated with a poor prognosis in several diseases, and particularly in IPF. In a large Korean cohort of patients with IPF, Lee and colleagues evaluated the prognosis of IPF according to the patients' work and found that the wood or chemical dust-exposure group showed the worst outcomes (4). This group displayed a greater annual decline in FVC% and a higher mortality compared with nonexposed patients, with a hazard ratio of 1.813 (95% confidence interval [CI], 1.049-3.133, P = 0.033) (4 Enlarged MLNs in ILDs may be at least in part a marker of occupational or environmental exposure. Thus, we may hypothesize that the prognostic impact of MLNs observed in the study by Adegunsoye and colleagues could be related to the negative effects of unrecognized exposures. It would have been interesting to look at the patients' occupational potential exposures, and ideally to perform a cytological analysis of MLNs to verify the presence or absence of lymph node anthracosis or anthracofibrosis in these patients. n
Reply to Lescoat et al. and to Khamis et al.

From the Authors:
We welcome the interest shown by Lescoat and colleagues and Khamis and colleagues in our publication (1), and thank the authors for their letters. Although the clinical value of plasma biomarkers is well established in many chronic disease states, we recognize that limitations exist regarding their use in prognostication of outcomes. As alluded to by Lescoat and colleagues, the magnitude of the prognostic effect for individual plasma biomarkers will likely vary across diverse forms of interstitial lung disease (ILD) and at different thresholds. Indeed, circulating plasma biomarker levels may be lower relative to biomarker concentrations within specific organs that are directly involved in tissue repair and homeostasis. Also, the extent of disease activity that typically occurs across multiple extrapulmonary organs, such as those affected in connective tissue disease associated with ILD, may accentuate this variation. With regard to IL-6, it has been suggested that this cytokine has a bidirectional role in the pathogenesis of lung fibrosis. Whereas IL-6 blockade at an early inflammatory stage can accelerate lung fibrosis, blockade at an early fibrotic stage may ameliorate subsequent fibrogenesis (2). These factors could conceivably account for the potentially favorable results that are observed when IL-6 is therapeutically targeted in scleroderma-associated ILD (3). We did find that mean plasma IL-6 levels were nonsignificantly decreased in subjects with enlarged mediastinal lymph nodes (MLNs) in our study, but chose to report median plasma cytokine values in our comparative analyses because these values are less subject to the influence of outliers (1). In both our primary and replication cohorts, the median plasma IL-6 levels did not differ by MLN size (Figure 1 ) and did not predict mortality risk. We therefore reiterate that we cannot conclude from the data presented in our study that IL-6 might be protective in fibrotic ILD, and agree with Lescoat and colleagues that further study of the blockade of IL-6 in clinical trials is warranted (1). Supported by NIH R21AI126031, NIH K23HL138190, NIH R01AI125644, and NIH R01HL130796.
